Buyze J
Johnson & Johnson, Beerse, Belgium.
ArticleKetamine
Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].
ArticleKetamine
Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".
ArticleKetamine
Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study.
ArticleKetamine
Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release.
ArticleKetamine
Top-line Results from ESCAPE-LTE: An Open-Label Extension Study to Assess Long-term Safety of Esketamine Nasal Spray in Treatment Resistant Depression
ArticleKetamine
Outcomes with esketamine nasal spray in patients with or without earlier partial or full response: post hoc analyses of ESCAPE TRD
ArticleKetamine
Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression.
ArticleKetamine
Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial.
ArticleKetamine
Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.
ArticleKetamine